Cipla Limited announced on November 3 that it has entered into definitive agreements to acquire a 100% stake in Inzpera Healthsciences Limited. Once the transaction closes, Inzpera will become a wholly owned subsidiary of Cipla, expanding Cipla’s footprint in paediatric and wellness healthcare categories.
Transaction details
- Purchase consideration: Approximately ₹110.65 crore.
- Enterprise value: ₹120 crore.
- Transaction type: Cash-based arrangement, subject to customary closing-date adjustments.
- Expected timeline: Completion is intended within one month from signing or at a mutually agreed date.
Strategic intent
The deal is intended to combine Inzpera’s paediatric and wellness formulations with Cipla’s distribution capabilities and operational scale. The parties expect the integration to support increased reach and growth in niche therapeutic segments following completion.
About Inzpera Healthsciences
Founded in 2016, Inzpera Healthsciences focuses on developing, manufacturing, and marketing paediatric and wellness pharmaceutical products designed to address unmet needs in child health and related wellness areas.
Summary
Cipla has signed definitive agreements to acquire Inzpera Healthsciences for about ₹110.65 crore in a cash transaction that carries an enterprise value of ₹120 crore. The transaction, subject to closing adjustments, is expected to conclude within approximately one month, at which point Inzpera will become Cipla’s wholly owned subsidiary, strengthening Cipla’s presence in paediatric and wellness segments.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.